 |
ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.
The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives. Information about financial results, conference calls, webcasts, and other information is posted on the Company’s website.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
Tyler Ehler
Senior Director, Investor Relations
[email protected]
ข่าวที่เกี่ยวข้อง
- HKSH Medical Group Named Asia’s first Photon-Counting CT Simulator Reference Site, Bringing Global Impacts on Precision Medicine and Medical Imaging with Siemens Healthineers
- Goodbaby International Announces First Quarter Revenue Performance
- TCL CSOT Successfully Tops Out t8 Project Ahead of Schedule, Accelerating Mass Production of IJP OLED Technology
- Gamehaus Holdings Inc. to Announce Unaudited Financial Results for the Third Quarter of Fiscal 2026 on June 8, 2026
